Cargando…
COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation
PURPOSE: The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic. METHODS AND MATERIAL...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Brachytherapy Society. Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172676/ https://www.ncbi.nlm.nih.gov/pubmed/32359937 http://dx.doi.org/10.1016/j.brachy.2020.04.005 |
_version_ | 1783524301878591488 |
---|---|
author | Williams, Vonetta M. Kahn, Jenna M. Harkenrider, Matthew M. Chino, Junzo Chen, Jonathan Fang, L. Christine Dunn, Emily F. Fields, Emma Mayadev, Jyoti S. Rengan, Ramesh Petereit, Daniel Dyer, Brandon A. |
author_facet | Williams, Vonetta M. Kahn, Jenna M. Harkenrider, Matthew M. Chino, Junzo Chen, Jonathan Fang, L. Christine Dunn, Emily F. Fields, Emma Mayadev, Jyoti S. Rengan, Ramesh Petereit, Daniel Dyer, Brandon A. |
author_sort | Williams, Vonetta M. |
collection | PubMed |
description | PURPOSE: The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic. METHODS AND MATERIALS: We review amassing evidence to help guide the management and timing of brachytherapy for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed expert opinion is provided. RESULTS: There may be a significant negative impact on oncologic outcomes for patients with gynecologic malignancies who have a delay in the timely completion of therapy. Delay of prostate or breast cancer treatment may also impact oncologic outcomes. If a treatment delay is expected, endocrine therapy may be an appropriate temporizing measure before delivery of radiation therapy. The use of shorter brachytherapy fractionation schedules will help minimize patient exposure and conserve resources. CONCLUSIONS: Brachytherapy remains a critical treatment for patients and may shorten treatment time and exposure for some. Reduced patient exposure and resource utilization is important during COVID-19. Every effort should be made to ensure timely brachytherapy delivery for patients with gynecologic malignancies, and endocrine therapy may help temporize treatment delays for breast and prostate cancer patients. Physicians should continue to follow developing institutional, state, and federal guidelines/recommendations as challenges in delivering care during COVID-19 will continue to evolve. |
format | Online Article Text |
id | pubmed-7172676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Brachytherapy Society. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71726762020-04-22 COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation Williams, Vonetta M. Kahn, Jenna M. Harkenrider, Matthew M. Chino, Junzo Chen, Jonathan Fang, L. Christine Dunn, Emily F. Fields, Emma Mayadev, Jyoti S. Rengan, Ramesh Petereit, Daniel Dyer, Brandon A. Brachytherapy Article PURPOSE: The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic. METHODS AND MATERIALS: We review amassing evidence to help guide the management and timing of brachytherapy for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed expert opinion is provided. RESULTS: There may be a significant negative impact on oncologic outcomes for patients with gynecologic malignancies who have a delay in the timely completion of therapy. Delay of prostate or breast cancer treatment may also impact oncologic outcomes. If a treatment delay is expected, endocrine therapy may be an appropriate temporizing measure before delivery of radiation therapy. The use of shorter brachytherapy fractionation schedules will help minimize patient exposure and conserve resources. CONCLUSIONS: Brachytherapy remains a critical treatment for patients and may shorten treatment time and exposure for some. Reduced patient exposure and resource utilization is important during COVID-19. Every effort should be made to ensure timely brachytherapy delivery for patients with gynecologic malignancies, and endocrine therapy may help temporize treatment delays for breast and prostate cancer patients. Physicians should continue to follow developing institutional, state, and federal guidelines/recommendations as challenges in delivering care during COVID-19 will continue to evolve. American Brachytherapy Society. Published by Elsevier Inc. 2020 2020-04-21 /pmc/articles/PMC7172676/ /pubmed/32359937 http://dx.doi.org/10.1016/j.brachy.2020.04.005 Text en © 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Williams, Vonetta M. Kahn, Jenna M. Harkenrider, Matthew M. Chino, Junzo Chen, Jonathan Fang, L. Christine Dunn, Emily F. Fields, Emma Mayadev, Jyoti S. Rengan, Ramesh Petereit, Daniel Dyer, Brandon A. COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation |
title | COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation |
title_full | COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation |
title_fullStr | COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation |
title_full_unstemmed | COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation |
title_short | COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation |
title_sort | covid-19 impact on timing of brachytherapy treatment and strategies for risk mitigation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172676/ https://www.ncbi.nlm.nih.gov/pubmed/32359937 http://dx.doi.org/10.1016/j.brachy.2020.04.005 |
work_keys_str_mv | AT williamsvonettam covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT kahnjennam covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT harkenridermatthewm covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT chinojunzo covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT chenjonathan covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT fanglchristine covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT dunnemilyf covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT fieldsemma covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT mayadevjyotis covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT renganramesh covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT petereitdaniel covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation AT dyerbrandona covid19impactontimingofbrachytherapytreatmentandstrategiesforriskmitigation |